Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal
(Reuters) – Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc’s investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States. The Swiss drugmaker closed a $4.3 billion deal to acquire Sparks Therapeutics this month …
News story posted on 2019-12-25T11:43:00.0000000Z